BridgeBio Pharma, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(166,555) | $(169,608) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 33,242 | 25,882 |
| Net loss from equity method investments | 18,283 | 15,556 |
| Noncash interest expense on deferred royalty obligations (1) | 39,873 | 24,020 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | (2,158) | (3,952) |
| Amortization of debt discount and issuance costs | 1,819 | 1,621 |
| Depreciation and amortization | 1,186 | 1,284 |
| Noncash lease expense | 1,466 | 994 |
| Loss on extinguishment of debt | — | 21,155 |
| Other noncash adjustments, net | 306 | (21) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (65,782) | (110,543) |
| Inventories | (7,053) | (3,193) |
| Prepaid expenses and other current assets | (18,845) | (487) |
| Other assets | (1,795) | 1,587 |
| Accounts payable | (7,170) | 17,571 |
| Accrued compensation and benefits | (37,476) | (19,363) |
| Accrued research and development liabilities | 12,994 | (642) |
| Operating lease liabilities | (1,852) | (1,470) |
| Deferred revenue | (2,379) | (2,571) |
| Other liabilities (2) | 4,617 | 2,945 |
| Net cash used in operating activities | (197,279) | (199,235) |
| Investing activities: | ||
| Purchases of marketable securities | (52,666) | — |
| Maturities of marketable securities | 10,000 | — |
| Payment for an intangible asset | — | (1,595) |
| Purchases of property and equipment | (69) | — |
| Net cash used in investing activities | (42,735) | (1,595) |
| Financing activities: | ||
| Proceeds from issuance of 2033 Notes | 632,500 | — |
| Issuance costs and discounts associated with 2033 Notes | (12,796) | — |
| Proceeds from issuance of 2031 Notes | — | 575,000 |
| Issuance costs and discounts associated with 2031 Notes | — | (12,034) |
| Repurchase of common stock | (82,500) | (48,276) |
| Repayment of term loans | — | (459,000) |
| Repayments of deferred royalty obligations (3) | (11,293) | (144) |
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 2,521 |
| Transactions with noncontrolling interests | — | 800 |
| Repurchase of RSU shares to satisfy tax withholding | (4,074) | (1,776) |
| Net cash provided by financing activities | 549,892 | 60,328 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 309,878 | (140,502) |
| Cash, cash equivalents, and restricted cash at beginning of period | 572,140 | 683,244 |
| Cash, cash equivalents, and restricted cash at end of period | $882,018 | $542,742 |
(1)Including a related party amount of $5,361 for the three months ended March 31, 2026 (as described in Note 9).
(2)Including a related party amount of $3,622 for the three months ended March 31, 2026 (as described in Note 9).
(3)Including a related party amount of $(2,024) for the three months ended March 31, 2026 (as described in Note 9).
\
Condensed Consolidated Statements of Cash Flows
(Continued)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for interest | $20,316 | $23,271 |
| Supplemental Disclosures of Noncash Investing and Financing Information: | ||
| Unpaid issuance costs associated with 2033 Notes | $431 | $— |
| Unpaid property and equipment | $12 | $337 |
| Transfers to noncontrolling interests | $(1,955) | $(824) |
| Recognized intangible asset recorded to “Other current liabilities” | $— | $4,500 |
| Reconciliation of Cash, Cash Equivalents and Restricted Cash: | ||
| Cash and cash equivalents | $879,891 | $540,599 |
| Restricted cash — Included in “Prepaid expenses and other current assets” | 550 | 126 |
| Restricted cash — Included in “Other assets” | 1,577 | 2,017 |
| Total cash, cash equivalents and restricted cash at end of periods shown on the condensed consolidated statements of cash flows | $882,018 | $542,742 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.